Cluster of Differentiation 163 Level in the Blood as a Predictor of Early and Late Onset Neonatal Sepsis | ||||
| The Egyptian Journal of Hospital Medicine | ||||
| Article 91, Volume 96, Issue 1, July 2024, Page 2936-2941 PDF (618.75 K) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ejhm.2024.375542 | ||||
 View on SCiNiTO | ||||
| Abstract | ||||
| Background: Early and late-onset neonatal sepsis (EOS and LOS) are significant causes of morbidity and mortality in newborns. Accurate and timely diagnosis is critical for effective management. The Cluster of Differentiation 163 (CD163) level in the blood has emerged as a potential biomarker for sepsis, reflecting the immune response to infection. Objective: This study aimed to evaluate the role of CD163 levels in predicting neonatal sepsis and its correlation with other clinical and laboratory parameters. Methods: A comparative study was conducted involving 90 neonates divided into three groups: EOS, LOS, and a control group. Clinical data, presenting complaints, maternal risk factors, and laboratory findings were analyzed. CD163 levels were measured and correlated with clinical outcomes. Results: CD163 concentrations were markedly higher in both EOS and LOS cohorts relative to the control group. In the LOS cohort, CD163 levels demonstrated a positive association with platelet count and an inverse relationship with hemoglobin concentrations. No significant gender differences in CD163 levels were observed. Conclusion: CD163 serves as a critical biomarker for the prompt identification of neonatal sepsis, with a threshold value set at ≥ 4.5%. Its use in clinical practice could enhance early diagnosis and treatment as well as reduction of neonatal morbidity and mortality. | ||||
| Keywords | ||||
| Neonatal sepsis; CD163; Biomarkers; Late-onset sepsis; Early-onset sepsis; Maternal risk factors | ||||
|
Statistics Article View: 100 PDF Download: 127 |
||||
